Cystadenocarcinoma
A malignant neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. The neoplastic cells manifest varying degrees of anaplasia and invasiveness, and local extension and metastases occur. Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (Stedman, 25th ed)
Cystadenocarcinoma, Mucinous
A malignant cystic or semisolid tumor most often occurring in the ovary. Rarely, one is solid. This tumor may develop from a mucinous cystadenoma, or it may be malignant at the onset. The cysts are lined with tall columnar epithelial cells; in others, the epithelium consists of many layers of cells that have lost normal structure entirely. In the more undifferentiated tumors, one may see sheets and nests of tumor cells that have very little resemblance to the parent structure. (Hughes, Obstetric-Gynecologic Terminology, 1972, p184)
Cystadenoma
Cystadenocarcinoma, Papillary
Cystadenocarcinoma, Serous
A malignant cystic or semicystic neoplasm. It often occurs in the ovary and usually bilaterally. The external surface is usually covered with papillary excrescences. Microscopically, the papillary patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma cells. Psammoma bodies may be present. The tumor generally adheres to surrounding structures and produces ascites. (From Hughes, Obstetric-Gynecologic Terminology, 1972, p185)
Cystadenoma, Mucinous
Mucocele
Cysts
Pyonephrosis
Mixed Tumor, Mesodermal
Ovarian Neoplasms
Biliary Tract Neoplasms
Barium Sulfate
Pseudomyxoma Peritonei
A condition characterized by poorly-circumscribed gelatinous masses filled with malignant mucin-secreting cells. Forty-five percent of pseudomyxomas arise from the ovary, usually in a mucinous cystadenocarcinoma (CYSTADENOCARCINOMA, MUCINOUS), which has prognostic significance. Pseudomyxoma peritonei must be differentiated from mucinous spillage into the peritoneum by a benign mucocele of the appendix. (Segen, Dictionary of Modern Medicine, 1992)
Bile Ducts, Intrahepatic
Pancreatic Neoplasms
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
Tomography, X-Ray Computed
Pancreaticoduodenectomy
Carcinoma, Endometrioid
Epididymal Secretory Proteins
CA-125 Antigen
Encyclopedias as Topic
Fallopian Tube Neoplasms
Fallopian Tubes
A pair of highly specialized muscular canals extending from the UTERUS to its corresponding OVARY. They provide the means for OVUM collection, and the site for the final maturation of gametes and FERTILIZATION. The fallopian tube consists of an interstitium, an isthmus, an ampulla, an infundibulum, and fimbriae. Its wall consists of three histologic layers: serous, muscular, and an internal mucosal layer lined with both ciliated and secretory cells.
Neoplasms, Glandular and Epithelial
Leukocytes, Mononuclear
Down-Regulation
Paclitaxel
Antineoplastic Combined Chemotherapy Protocols
Antineoplastic Agents, Phytogenic
Histocompatibility Antigens Class II
Large, transmembrane, non-covalently linked glycoproteins (alpha and beta). Both chains can be polymorphic although there is more structural variation in the beta chains. The class II antigens in humans are called HLA-D ANTIGENS and are coded by a gene on chromosome 6. In mice, two genes named IA and IE on chromosome 17 code for the H-2 antigens. The antigens are found on B-lymphocytes, macrophages, epidermal cells, and sperm and are thought to mediate the competence of and cellular cooperation in the immune response. The term IA antigens used to refer only to the proteins encoded by the IA genes in the mouse, but is now used as a generic term for any class II histocompatibility antigen.
Antigen Presentation
The process by which antigen is presented to lymphocytes in a form they can recognize. This is performed by antigen presenting cells (APCs). Some antigens require processing before they can be recognized. Antigen processing consists of ingestion and partial digestion of the antigen by the APC, followed by presentation of fragments on the cell surface. (From Rosen et al., Dictionary of Immunology, 1989)
HLA-D Antigens
Human immune-response or Class II antigens found mainly, but not exclusively, on B-lymphocytes and produced from genes of the HLA-D locus. They are extremely polymorphic families of glycopeptides, each consisting of two chains, alpha and beta. This group of antigens includes the -DR, -DQ and -DP designations, of which HLA-DR is most studied; some of these glycoproteins are associated with certain diseases, possibly of immune etiology.
HLA-DQ Antigens
HLA-DR Antigens
Artificial Intelligence
HLA Antigens
PubMed
A bibliographic database that includes MEDLINE as its primary subset. It is produced by the National Center for Biotechnology Information (NCBI), part of the NATIONAL LIBRARY OF MEDICINE. PubMed, which is searchable through NLM's Web site, also includes access to additional citations to selected life sciences journals not in MEDLINE, and links to other resources such as the full-text of articles at participating publishers' Web sites, NCBI's molecular biology databases, and PubMed Central.
Publishing
MEDLINE
Serial Publications
Biological Science Disciplines
All of the divisions of the natural sciences dealing with the various aspects of the phenomena of life and vital processes. The concept includes anatomy and physiology, biochemistry and biophysics, and the biology of animals, plants, and microorganisms. It should be differentiated from BIOLOGY, one of its subdivisions, concerned specifically with the origin and life processes of living organisms.
Increased expression of the RIalpha subunit of the cAMP-dependent protein kinase A is associated with advanced stage ovarian cancer. (1/526)
The primary element in the cAMP signal transduction pathway is the cAMP-dependent protein kinase (PKA). Expression of the RIalpha subunit of type I PKA is elevated in a variety of human tumours and cancer cell lines. The purpose of this study was to assess the prognostic importance of RIalpha expression in patients with ovarian cancer. We have evaluated the expression of RIalpha in a panel of human ovarian tumours (n = 40) and five human ovarian cancer cell lines using quantitative reverse transcription polymerase chain reaction (RT-PCR) and Western blot analysis. The human ovarian cell lines OAW42 and OTN14 express high endogenous levels of RIalpha mRNA and protein (at significantly higher mRNA levels than high tissue expressors, P < 0.05). The ovarian cell line A2780 expresses low endogenous levels of RIalpha mRNA and protein (also at higher mRNA levels than low tissue expressors, P < 0.05). Quantitative RT-PCR revealed no significant difference in RIalpha mRNA expression between different ovarian histological subtypes in this study. No associations were found between RIalpha mRNA expression and differentiation state. RIalpha mRNA expression was significantly associated with tumour stage (P = 0.0036), and this remained significant in univariate analysis (P = 0.0002). A trend emerged between RIalpha mRNA expression levels and overall survival in univariate analysis (P = 0.051), however, by multivariate analysis, stage remained the major determinant of overall survival (P = 0.0001). This study indicates that in ovarian epithelial tumours high RIalpha mRNA expression is associated with advanced stage disease. RIalpha expression may be of predictive value in ovarian cancer and may be associated with dysfunctional signalling pathways in this cancer type. (+info)The expression of CCAAT/enhancer binding protein (C/EBP) in the human ovary in vivo: specific increase in C/EBPbeta during epithelial tumour progression. (2/526)
The CCAAT/enhancer binding protein (C/EBP) family of transcription factors is involved in metabolism and differentiation of cells, especially in rodent liver cells and adipocytes. Their roles in vivo and in particular during pathophysiological conditions in humans are largely unknown. We have investigated the presence of C/EBPalpha, -beta, -delta and -zeta in normal ovaries and in epithelial ovarian tumours of different stages. Immunohistochemical experiments demonstrated that C/EBPalpha and C/EBPbeta were preferentially expressed in epithelial/tumour cells irrespective of stage or grade of the tumour. C/EBPbeta was located in the nuclei of the cells, in contrast to C/EBPalpha, which was present only in the cytoplasm of these cells. The nuclear localization of C/EBPbeta indicates an active role of this transcription factor in tumour cells, whereas the cytoplasmic distribution suggests a more passive function of C/EBPalpha. C/EBPdelta and -zeta demonstrated a more diverse distribution with predominant localization to epithelial cells, but stromal distribution was also noted. The intracellular distribution was confined to both the nucleus and the cytoplasm for C/EBPdelta and -zeta. Western blotting demonstrated that C/EBPalpha, -beta, -delta and -zeta were present in a majority of the samples. The amount of C/EBPbeta increased markedly with malignancy, i.e. with degree of dedifferentiation, while the other members of the C/EBP family displayed a more constant expression level. These results demonstrate an association between the expression of members of the C/EBP family and the formation of epithelial ovarian tumours, with C/EBPbeta as a potential marker for these tumours. As C/EBPbeta is known to be expressed during proliferation of cells in vitro, it may participate in the proliferative process of ovarian epithelial tumour cells in vivo and play a central role in tumour progression. (+info)Overexpression of H-Ryk in mouse fibroblasts confers transforming ability in vitro and in vivo: correlation with up-regulation in epithelial ovarian cancer. (3/526)
Abnormalities in the function of receptor tyrosine kinases (RTKs) have been demonstrated to be important in the pathogenesis of cancer. H-Ryk, a new member of the RTK family, is an unusual RTK in that it is catalytically inactive because of amino acid substitutions of conserved residues in the catalytic domain. We show by immunohistochemistry that it is expressed in the epithelium, stroma, and blood vessels of normal tissues. Evaluation of a panel of 33 primary ovarian tumors (2 benign, 8 borderline, and 23 malignant) was performed. H-Ryk was overexpressed in borderline and malignant ovarian tumors. In serous and clear cell subtypes, there was increased expression in the epithelium, stroma, and blood vessels. Consistent with this observation, overexpression of H-Ryk in the mouse fibroblast cell line NIH3T3 induces anchorage-independent growth and tumorigenicity in nude mice. This implies that overexpression of the receptor can be transforming and may therefore be significant in the pathogenesis of ovarian cancer. (+info)Borderline ovarian tumours in Vaud, Switzerland: incidence, survival and second neoplasms. (4/526)
Between 1976 and 1996, 176 borderline ovarian tumours were registered in the Cancer Registry of the Swiss canton of Vaud, corresponding to an age-adjusted incidence (world standard) of 2.7 in 100,000. Incidence rose from 1.7 per 100,000 during 1976-81 to 2.7 per 100,000 during 1987-91, and then levelled off; 58% of cases were serous and 41% mucinous. Relative survival was 94% at 10 years; 18 second neoplasms were observed, compared with 10.3 expected, and there was a significant excess of invasive ovarian cancers (four observed, including three synchronous, compared with 0.4 expected). (+info)Three dimensional ultrasound and power doppler in assessment of uterine and ovarian angiogenesis: a prospective study. (5/526)
AIM: To determine whether three-dimensional power Doppler can improve the recognition of pelvic tumor morphology and angiogenesis. METHODS: Using this technique we analyzed 180 adnexal masses and 110 uterine lesions. Tumor volume, morphology, and vascularity were evaluated in each patient. Irregular and randomly dispersed vessels with complex branching depicted by comprehensive three dimensional display were suggestive of pelvic malignancy, while linear-like vascular morphology, single vessel arrangement and regular branching were typical for benign structures. RESULTS: Addition of qualitative analysis of vascular architecture of adnexal tumor to morphological parameters reached 96.15% sensitivity and 98.73% specificity. When endometrial lesions were prospectively analyzed, sensitivity and specificity were 91.67% and 98.49%, respectively. Because the lowest positive predictive value of 16.67% was obtained for myometrial lesions, this method should not be advised for their eva luation. CONCLUSION: Good results achieved by three dimensional ultrasound can be explained by improved recognition of the pelvic lesion anatomy, characterization of the surface features, detection of the tumor infiltration, and precise depiction of the size and volume. Three dimensional power Doppler imaging can detect structural abnormalities of the malignant tumor vessels, such as arteriovenous shunts, microaneurysms, tumoral lakes, disproportional calibration, coiling, and dichotomous branching. Therefore it enhances and facilitates the morphologic and functional evaluation of both benign and malignant pelvic tumors. (+info)Evaluation of the tyrosine kinase domain of the Met proto-oncogene in sporadic ovarian carcinomas*. (6/526)
Most of the ovarian cancers originate from the ovarian surface epithelium derived from the coelomic mesothelium. The Met proto-oncogene encodes a transmembrane tyrosine kinase receptor (Met) that has the capacity to regulate cell proliferation and differentation and it is activated by hepatocyte growth factor. Trisomy of chromosome 7 and Met protein overexpression have been were observed in ovarian carcinomas, the papillary renal cancers and other solid tumors. Frequent mutations of Met proto-oncogene have been found in hereditary papillary renal cancer (HPRC) and most of the mutations are located in the tyrosine kinase domain. The aim of this study to perform a mutation analysis of exons 17 19 of Met proto-oncogene in epithelial ovarian tumors (EOTs). We have examined 24 tumor samples from patients, operated with EOTs. Mutation was detected in exon 18 in only one sample of 24 EOTs. Our results indicate that mutations located in the Met proto-oncogene is not a common event in EOT. It is not clear whether the mutation plays a role in the tumorigenesis or progression of EOT or not. (+info)Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors. (7/526)
The purpose of this study was to investigate the frequency of p53 overexpression in the primary ovarian tumors of patients with stages II and III serous borderline tumors (SBTs) and to determine the relationship between p53 overexpression and risk of progression/recurrence and survival. Of 112 patients with stages II-IV SBTs, paraffin-embedded tissue from the primary ovarian tumor was available in 68 cases. Immunohistochemical staining for p53 was performed. Clinical information was abstracted from the medical records. The major end points selected for analysis were time to progression/relapse, disease-free survival, overall survival, and cause-specific survival. Univariate and multivariate regression analyses were also performed. The median patient age was 37 years (range, 17-67 years). Twenty-two patients had stage II disease, and 46 had stage III disease. The mean follow-up time was 105 months. Nineteen patients (28%) had either disease progression (1 patient) or relapse (18 patients). Eleven patients died: 10 patients died of their tumor, and 1 patient died of other causes. Thirteen cases (19%) had positive immunostaining for p53. Overexpression of p53 was significantly associated with an increased probability of progression/recurrence (P = 0.005) and a decreased overall survival (P = 0.012). After adjusting for age, International Federation of Gynecology and Obstetrics (FIGO) stage, the presence of residual tumor, and the presence of invasive implants, patients whose tumors overexpressed p53 had a 4-fold increased risk of progression/ recurrence. Similarly, women whose tumor overexpressed p53 had an approximately 6-fold increased risk of death. p53 overexpression in the ovarian tumors of patients with stage II and III SBTs is significantly associated with increased probability of relapse and decreased overall survival. This information should provide better prognostic data to patients and their families and allow us to select patients who might benefit from postoperative treatment. (+info)Allelotyping defines minimal imbalance at chromosomal region 17q25 in non-serous epithelial ovarian cancers. (8/526)
Allelic deletions of multiple chromosome 17q loci in sporadic ovarian cancer of epithelial origin suggest that inactivation of tumor suppressor gene(s) in these regions may be important for ovarian tumorigenesis. To further define the pattern of allelic imbalance in epithelial ovarian tumors of different histologies, a PCR-based assay was used to assess loss of heterozygosity (LOH) of polymorphic markers representative of TP53, BRCA1, NME1 and GH1, and region 17q23-25. LOH was observed for at least one marker in 68% of malignant tumors (n=60) and in 18% tumors of borderline malignancy (n=11), but not in benign tumors (n=5). The highest frequency of LOH in malignant tumors (64%) was observed with D17S801 on 17q25. Ten of 39 malignant ovarian tumors displaying LOH of at least one 17q marker, displayed a LOH pattern enabling the determination of a minimal region of overlapping deletion defined by D17S795 and D17S801. One borderline tumor also displayed an interstitial LOH pattern that overlapped this 17q25 minimal region of deletion. The histologies of malignant tumors displaying a pattern indicative of interstitial 17q deletions were of the endometrioid, clear cell and mucinous epithelial types. As the minimal region of overlap defined by these tumors overlap regions deleted in malignant tumors of all histologic types, and in a tumor of borderline malignancy, the 17q25-tumor suppressor may be implicated in the development of all types of epithelial ovarian tumors. (+info)
GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma.
Malignant Ovarian Serous Tumor - My Cancer Genome
TP53 Gene Mutation Found in 80% of High Grade Ovarian Serous Carcinomas; TP53 Not Directly Involved In The Development of Drug...
Gene expression analysis identifies two groups of ovarian high-grade serous carcinomas with different prognosis<...
Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than...
Dishevelled family proteins in serous ovarian carcinomas: A clinicopathologic and molecular study
Uterine Serous Carcinoma
High expression of NQO1 is associated with poor prognosis in serous ovarian carcinoma | BMC Cancer | Full Text
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. - Cancer Epidemiology Unit (CEU)
Molecular Characterization of an Intact p53 Pathway Subtype in High-Grade Serous Ovarian Cancer
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
Preservation of stemness in high-grade serous ovarian cancer organoids requires low Wnt environment - EGA European Genome...
TBX2 expression is associated with platinum‑sensitivity of ovarian serous carcinoma
Events Archive - ISGyP
Plus it
Plus it
Impact of lymph node ratio on survival in stage III ovarian high-grade serous cancer: a Turkish Gynecologic Oncology Group study
Benign and Low Grade Serous Epithelial Tumors: Recent Developments and Diagnostic Problems. - Semantic Scholar
Study Identifies Cells-of-origin of High-grade Serous Ovarian Cancer - OncoZine
High expression of NQO1 is associated with poor prognosis in serous ovarian carcinoma - pdf descargar
diagnosis of ovarian tumors - Humpath.com - Human pathology
JCI -
An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice
GRAF | Cancer Genetics Web
Low Grade Serous Ovarian Cancer - United States
Prognostic significance of Notch 3 gene expression in ovarian serous carcinoma
Ovarian cancer in lymph nodes. Chisturi de giardia în scaunul uman
High PTPN13 expression in high grade serous ovarian carcinoma is associated with a better patient outcome | Oncotarget
Daniel J. Powell Jr. | Faculty | Center for Research on Reproduction and Womens Health | Perelman School of Medicine at the...
UPENN Biomedical Graduate Studies | Daniel J. Powell Jr.
Plus it
PNNL: BTRR Proteomics Resource - Publications
KRAS Mutation in Serous Borderline Tumor of the Testis: Report of a Case and Review of the Literature
Low-grade serous carcinoma (mullerian/ovarian type) of the paratestis presenting as diffuse metastatic disease of unknown...
Outcome after combined modality treatment for uterine papillary serous carcinoma: A study by the Rare Cancer Network (RCN)<...
Ovarian serous cystadenofibromas associated with a low-grade serous carcinoma of the peritoneum<...
Cervical Serous Adenocarcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials
A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma - Full Text...
Impact of tubal ligation on routes of dissemination and overall survival in uterine serous carcinoma<...
Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes
Mass spectrometry-based peptidome profiling of human serous ovarian cancer tissues | Bioinformatics Solutions Inc.
Uterine papillary serous carcinoma: A rare type of endometrial carcinoma with worse outcomes-IJOGR-IP Innovative Publication...
Precursor Lesions of High-Grade Serous Ovarian Carcinoma: Morphological and Molecular Characteristics
Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct...
CAISMOV24, a new human low-grade serous ovarian carcinoma cell line | BMC Cancer | Full Text
Is invasive micropapillary serous carcinoma a low-grade carcinoma?<...
MRI appearance of ovarian serous borderline tumors of the micropapillary type compared to that of typical ovarian serous...
uterine serous carcinoma survival rates
Most recent papers with the keyword Uterine serous cancer | Read by QxMD
Uterine Papillary Serous Carcinoma (UPSC): any others here??? | Cancer Survivors Network
Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis...
5 Easy Facts About best provestra review Described
Plus it
Stefanie Ueda, MD | Obstetrics, Gynecology & Reproductive Sciences
Plus it
Michele Cote - Oncology - Wayne State University
Definition and Algorithm | Ovarian Cancer Prevention, Detection and Treatment
Augmentation of Response to Chemotherapy by microRNA-506 Through Regulation of RAD51 in Serous Ovarian Cancers<...
Are Epithelial Ovarian Cancers of the Mesenchymal Subtype Actually Intraperitoneal Metastases to the Ovary?
Papillary serous ovarian carcinoma | Case Studies
A Comparison of WT1, PTEN and the AKT Pathway in Ovarian Serous Carcinoma vs. Colorectal Adenocarcinoma - Research Database,...
Plus it
The role of vaginal brachytherapy in stage I endometrial serous cancer: a systematic review
JCDR - Citation Manager Cite this Article Clinico Pathological Analysis of Uterine Serous Carcinoma in a Cancer Centre from...
Flaviopierleoni » GuestBook
Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. - PubMed - NCBI
Reseach reveals genomic similarities between breast cancer, ovarian cancers
CiNii Articles - Yoshinaga Kousuke
Ovarian Cancer Development and Metastasis - ScienceOpen
A Study Combining the Peposertib (M3814) Pill with Standard Chemotherapy in Patients with Ovarian Cancer with an Expansion in...
Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer...
My Faux Eyebrows
Tumor apelin immunoreactivity is correlated with body mass index in ovarian high grade serous carcinoma. | AVESİS
Psammoma body
Ovarian papillary serous cystadenocarcinoma at WebPath, The Internet Pathology Laboratory for Medical Education at Mercer ... renal cell carcinoma Micropapillary subtype of lung adenocarcinoma Ovarian papillary serous cystadenoma and cystadenocarcinoma ... Endometrial adenocarcinomas (Papillary serous carcinoma ~3%-4%) Meningiomas, in the central nervous system Peritoneal and ...
International Cancer Genome Consortium
... ovarian serous cystadenocarcinoma, lung squamous cell carcinoma, adrenocortical carcinoma, Diffuse Large B-cell lymphoma, ... Serous cystadenocarcinoma Canada: Pancreatic Cancer - Ductal adenocarcinoma and Prostate Cancer - Adenocarcinoma China: Gastric ...
Fibroblast growth factor receptor 1
... of ovarian Papillary serous cystadenocarcinoma (almost all amplifications); ~5% of colorectal cancers (~60 amplifications, 40% ...
Cystadenocarcinoma
Papillary serous cystadenocarcinoma "Female Genital Pathology". Retrieved 2009-03-23. King JC, Ng TT, White SC, Cortina G, ... "Pancreatic serous cystadenocarcinoma: a case report and review of the literature". J Gastrointest Surg. 13 (10): 1864-8. doi: ... Cystadenocarcinoma is a malignant form of a cystadenoma and is a malignant neoplasm derived from glandular epithelium, in which ... Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. Similar tumor ...
Cystadenoma
ISBN 978-1-4160-2999-1. Serous cystadenoma of pancreas at eMedicine Biliary cystadenoma/cystadenocarcinoma at eMedicine v t e. ... When malignant, it is called cystadenocarcinoma. When not otherwise specified, the ICD-O coding is 8440/0. However, the ... following classifications also exist: serous cystadenoma (8441-8442) papillary cystadenoma (8450-8451, 8561) mucinous ...
Ovarian cancer
It includes serous tumor, endometrioid tumor, and mucinous cystadenocarcinoma. Less common tumors are malignant Endometrioid ... Serous carcinomas are thought to begin in the Fallopian tube. Histologically, serous adenocarcinomas have psammoma bodies. Low- ... Serous carcinomas may develop from serous tubal intraepithelial carcinoma, rather than developing spontaneously from ovarian ... Low-grade serous carcinoma is less aggressive than high-grade serous carcinomas, though it does not typically respond well to ...
SK-OV-3
... ovarian cancer cell line derived from the ascites of a 64-year-old Caucasian female with an ovarian serous cystadenocarcinoma. ...
Carcinoid
Serous. *Ovarian serous cystadenoma / Pancreatic serous cystadenoma / Serous cystadenocarcinoma / Papillary serous ...
Carcinoma
Serous. *Ovarian serous cystadenoma / Pancreatic serous cystadenoma / Serous cystadenocarcinoma / Papillary serous ...
Somatostatinoma
Serous. *Ovarian serous cystadenoma / Pancreatic serous cystadenoma / Serous cystadenocarcinoma / Papillary serous ...
Hepatocellular adenoma
Serous. *Ovarian serous cystadenoma / Pancreatic serous cystadenoma / Serous cystadenocarcinoma / Papillary serous ...
Linitis plastica
Serous. *Ovarian serous cystadenoma / Pancreatic serous cystadenoma / Serous cystadenocarcinoma / Papillary serous ...
Multiple endocrine neoplasia
Serous. *Ovarian serous cystadenoma / Pancreatic serous cystadenoma / Serous cystadenocarcinoma / Papillary serous ...
Warthin's tumor
Serous. *Ovarian serous cystadenoma / Pancreatic serous cystadenoma / Serous cystadenocarcinoma / Papillary serous ...
Prolactinoma
Serous. *Ovarian serous cystadenoma / Pancreatic serous cystadenoma / Serous cystadenocarcinoma / Papillary serous ...
Papilloma
Serous. *Ovarian serous cystadenoma / Pancreatic serous cystadenoma / Serous cystadenocarcinoma / Papillary serous ...
Ovary
Ovarian serous cystadenoma. *Mucinous cystadenoma. *Cystadenocarcinoma *Papillary serous cystadenocarcinoma. *Krukenberg tumor ...
Leukotriene B4 receptor 2
... the Serous cystadenocarcinoma type of ovarian cancer, and uterine cervical carcinoma. Other studies have implicated BLT2 in ...
Sarcoma botryoides
Ovarian serous cystadenoma. *Mucinous cystadenoma. *Cystadenocarcinoma *Papillary serous cystadenocarcinoma. *Krukenberg tumor ...
Granulosa cell tumour
Ovarian serous cystadenoma. *Mucinous cystadenoma. *Cystadenocarcinoma *Papillary serous cystadenocarcinoma. *Krukenberg tumor ...
Estrogen receptor beta
... ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-beta in neoplastic tissues". The Journal ...
List of MeSH codes (C04)
... cystadenocarcinoma, papillary MeSH C04.557.470.200.025.480.240 - cystadenocarcinoma, serous MeSH C04.557.470.200.025.540 - ... cystadenocarcinoma, papillary MeSH C04.557.470.590.480.240 - cystadenocarcinoma, serous MeSH C04.557.470.590.485 - cystadenoma ... cystadenocarcinoma MeSH C04.557.470.200.025.480.225 - cystadenocarcinoma, mucinous MeSH C04.557.470.200.025.480.230 - ... cystadenocarcinoma MeSH C04.557.470.590.480.225 - cystadenocarcinoma, mucinous MeSH C04.557.470.590.480.230 - ...
Surface epithelial-stromal tumor
75% are benign or of borderline malignancy, and 25% are malignant The malignant form of this tumor, serous cystadenocarcinoma, ... lined by tall, columnar, ciliated epithelial cells filled with clear serous fluid the term serous which originated as a ... Malignant serous tumors occur later in life on average, although somewhat earlier in familial cases. 20% of benign, 30% of ... The overall prognosis is somewhat worse than for serous or mucinous tumors, and the 5-year survival rate for patients with ...
Pancreatectomy
... mucinous/serous) Cystadenocarcinoma Islet cell tumors (neuroendocrine tumors) Papillary cystic neoplasms Lymphoma Acinar cell ...
International Classification of Diseases for Oncology
NOS Serous cystoma Serous microcystic adenoma M8441/3 Serous cystadenocarcinoma, NOS (C56.9) Serous adenocarcinoma, NOS Serous ... M8460/0 Papillary serous cystadenoma, NOS (C56.9) M8460/3 Papillary serous cystadenocarcinoma (C56.9) Papillary serous ... Serous cystadenofibroma of borderline malignancy M9014/3 Serous adenocarcinofibroma Malignant serous adenofibroma Serous ... M8461/3 Serous surface papillary carcinoma (C56.9) Primary serous papillary carcinoma of peritoneum (C48.1) M8462/1 Serous ...
Testicular cancer
... borderline malignancy Serous carcinoma Well differentiated endometrioid tumor Mucinous cystadenoma Mucinous cystadenocarcinoma ... lymphoma of the testes pediatric-type follicular lymphoma of the testes Carcinoid Tumors of ovarian epithelial types Serous ...
Cystic lesions of the pancreas
Pancreatic serous cystadenoma Pancreatic serous cystadenocarcinoma Pancreatic mucinous cystic tumors (13.4%) Pancreatic ... Pancreatic intraductal papillary mucinous tumors (most common diagnosis - 52.6%) Pancreatic serous cystic tumors (20.6%) ... mucinous cystadenoma Pancreatic mucinous cystadenocarcinoma Parra-Herran, C. E.; Garcia, M. T.; Herrera, L; Bejarano, P. A. ( ...
Serous cystadenocarcinoma
... is a type of tumor in the cystadenocarcinoma grouping. Most commonly, the primary site of serous ... August 2005). "Serous cystadenocarcinoma of the pancreas: management of a rare entity". Pancreas. 31 (2): 182-7. doi:10.1097/01 ... 13(10):1864-8 (October 2009). "Pancreatic serous cystadenocarcinoma: a case report and review of the literature". Cite journal ... with the majority of microcystic pancreatic masses representing alternate disease processes such as the more benign serous ...
Pancreatic serous cystadenoma
... "serous cystadenocarcinoma".[citation needed] These lesions rarely require surgery unless they are symptomatic or the diagnosis ... Those that are benign, that have not spread to other organs, are designated "serous cystadenoma". Serous cystadenomas can be ... There are some exceptions; rare case reports have described isolated malignant serous cystadenocarcinomas. In addition, serous ... Pancreatic serous cystadenoma is a benign tumour of pancreas. It is usually found in the tail of the pancreas, and may be ...
Adenomyoma
Ovarian serous cystadenoma. *Mucinous cystadenoma. *Cystadenocarcinoma *Papillary serous cystadenocarcinoma. *Krukenberg tumor ...
印戒细胞癌 - 维基百科,自由的百科全
卵巢浆液性囊腺瘤 / Pancreatic serous cystadenoma(英语:Pancreatic serous cystadenoma) / Serous cystadenocarcinoma(英语:Serous ... 粘液性囊腺瘤 / Mucinous cystadenocarcinoma(英语:Mucinous cystadenocarcinoma) *Pseudomyxoma peritonei(英语:Pseudomyxoma peritonei) ... 囊性肿瘤: 浆液性微
Mucinous cystadenoma
Biliary cystadenoma and cystadenocarcinoma constitute less than 5% of intrahepatic cysts originating from the bile duct. ... On an average, mucinous accounts for 40%-50% of cystic tumors, and serous cytadenoma accounts for 30% of it. Mucinous ...
Papillary serous cystadenocarcinoma
Ovarian papillary serous cystadenocarcinoma at WebPath, The Internet Pathology Laboratory for Medical Education at Mercer ... Papillary serous cystadenocarcinomas may exhibit psammoma bodies upon histopathology. Papillary serous cystadenoma Kosary, ... Papillary serous cystadenocarcinomas are the most common form of malignant ovarian cancer making up 26 percent of ovarian ...
Serous cystadenocarcinoma - Wikipedia
Serous cystadenocarcinoma is a type of tumor in the cystadenocarcinoma grouping. Most commonly, the primary site of serous ... August 2005). "Serous cystadenocarcinoma of the pancreas: management of a rare entity". Pancreas. 31 (2): 182-7. doi:10.1097/01 ... 13(10):1864-8 (October 2009). "Pancreatic serous cystadenocarcinoma: a case report and review of the literature". Cite journal ... with the majority of microcystic pancreatic masses representing alternate disease processes such as the more benign serous ...
Papillary serous cystadenocarcinoma - Wikipedia
Ovarian papillary serous cystadenocarcinoma at WebPath, The Internet Pathology Laboratory for Medical Education at Mercer ... Papillary serous cystadenocarcinomas may exhibit psammoma bodies upon histopathology. Papillary serous cystadenoma Kosary, ... Papillary serous cystadenocarcinomas are the most common form of malignant ovarian cancer making up 26 percent of ovarian ...
Gastric metastasis of ovarian serous cystadenocarcinoma | IMCRJ
Gastric metastasis from ovarian serous cystadenocarcinoma is extremely rare. Case presentation: We herein report one case of a ... Gastric metastasis of ovarian serous cystadenocarcinoma Shiqiang Yang Xintai Hospital Affiliated to Taishan Medical University ... Background: Gastric metastasis from ovarian serous cystadenocarcinoma is extremely rare.. Case presentation: We herein report ...
Videos - Ovarian Histopathology - Serous Cyst Adenocarcinoma | DrugsUpdate India
37. Serous papillary cystadenocarcinoma of the ovary - greek.doctor
Serous cystadenocarcinoma of the pancreas: report of a case and management reflections | World Journal of Surgical Oncology |...
Serous cystic neoplasms of the pancreas carry a realistic risk of malignancy despite the general view that they never become ... In our opinion the treatment strategy of serous cystic neoplasms of the pancreas should be aggressive even in cases of remote ... A 86-year old patient known to have a serous cystadenoma of the pancreas treated conservatively through a close clinical and ... Serous adenomas represent 1-2% of pancreatic neoplasms and typically are asymptomatic not requiring any treatment and simple ...
Retraction note: Metastatic ovarian papillary cystadenocarcinoma to the small intestine serous surface: report of a case of...
Metastatic ovarian papillary cystadenocarcinoma to the small intestine serous surface: report of a case of high-grade ... Retraction note: Metastatic ovarian papillary cystadenocarcinoma to the small intestine serous surface: report of a case of ... Metastatic ovarian papillary cystadenocarcinoma to the small intestine serous surface: report of a case of high-grade ...
Familial association of specific histologic types of ovarian malignancy with other malignancies - Bermejo - 2004 - Cancer -...
... papillary serous cystadenocarcinoma was found to be associated with ovarian and skin malignancies and with myeloma; and ... risk of developing endometrioid carcinoma was slightly greater than the risk of developing papillary serous cystadenocarcinoma. ... Associations were found between endometrioid carcinoma and endometrial malignancy and between serous carcinoma and Hodgkin ...
A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma - Full Text...
Cystadenocarcinoma, Serous. Cystadenocarcinoma. Carcinoma. Uterine Neoplasms. Neoplasms, Glandular and Epithelial. Neoplasms by ... A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma. The safety and ... Uterine papillary serous carcinoma (UPSC) is an uncommon, but aggressive variant of endometrial carcinoma that has a high ... It has a propensity to metastasize throughout the abdomen, similar to serous carcinoma of the ovary. In fact, many patients ...
A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal...
Cystadenocarcinoma. Fallopian Tube Neoplasms. Carcinoma, Endometrioid. Cystadenocarcinoma, Serous. Cystadenocarcinoma, Mucinous ... Ovarian Mucinous Cystadenocarcinoma Ovarian Serous Cystadenocarcinoma Primary Peritoneal Carcinoma Recurrent Ovarian Carcinoma ... Fallopian Tube Carcinoma Malignant Ovarian Mixed Epithelial Tumor Ovarian Brenner Tumor Ovarian Clear Cell Cystadenocarcinoma ... Neoplasms, Cystic, Mucinous, and Serous. Fallopian Tube Diseases. Endometrial Neoplasms. Uterine Neoplasms. Neoplasms, ...
Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary...
Cystadenocarcinoma, Serous. Adenocarcinoma, Mucinous. Cystadenocarcinoma. Adenocarcinoma, Clear Cell. Neoplasms by Histologic ... Ovarian Serous Adenocarcinoma Primary Peritoneal Serous Adenocarcinoma Recurrent Fallopian Tube Carcinoma Recurrent Ovarian ... Participant may have serous, endometrioid, clear cell, mucinous or undifferentiated type of recurrent epithelial ovarian, ... Neoplasms, Cystic, Mucinous, and Serous. Bevacizumab. Pembrolizumab. Cyclophosphamide. Endothelial Growth Factors. Antibodies. ...
Cystadenocarcinoma - Wikipedia
Papillary serous cystadenocarcinoma "Female Genital Pathology". Retrieved 2009-03-23. King JC, Ng TT, White SC, Cortina G, ... "Pancreatic serous cystadenocarcinoma: a case report and review of the literature". J Gastrointest Surg. 13 (10): 1864-8. doi: ... Cystadenocarcinoma is a malignant form of a cystadenoma and is a malignant neoplasm derived from glandular epithelium, in which ... Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. Similar tumor ...
Evaluating and sharing global genetic ancestry in biomedical datasets. - PubMed - NCBI
Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endometrial Cancer - Full Text View -...
Cystadenocarcinoma. Neoplasms, Cystic, Mucinous, and Serous. Neoplasms, Complex and Mixed. Neoplasms, Connective and Soft ... Cystadenocarcinoma, Serous. Carcinosarcoma. Mixed Tumor, Mullerian. Adenocarcinoma, Clear Cell. Carcinoma. Neoplasms, Glandular ... Endometrial Clear Cell Adenocarcinoma Endometrial Endometrioid Adenocarcinoma Endometrial Serous Adenocarcinoma Stage I Uterine ... Histologically confirmed endometrial carcinoma: endometrioid type, serous, and clear cell, to include tumors originating in the ...
Predicting HLA class II antigen presentation through integrated deep learning | Nature Biotechnology
A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma - PubMed
Prognostic Role of Zinc Finger Homeobox 4 in Ovarian Serous Cystadenocarcinoma. Ha M, Kim J, Park SM, Hong CM, Han ME, Song P, ... A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma Wenna ... A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma Wenna ... Results: The methylation array data of 551 patients with ovarian serous cystadenocarcinoma (OSC) in The Cancer Genome Atlas ( ...
Similar articles for PubMed (Select 22066125) - PubMed - NCBI
Pancreatic serous cystadenocarcinoma with invasive growth into the colon and spleen.. Cho W, Cho YB, Jang KT, Kim HC, Yun SH, ... Pancreatic serous cystadenocarcinoma: a case report and review of the literature.. King JC, Ng TT, White SC, Cortina G, Reber ... Serous cystadenocarcinoma of the pancreas with portal thrombosis.. Vadalà S, Calderera G, Cinardi N, Manusia M, Li Volti G, ... A rare case of serous cystadenocarcinoma of the pancreas.. Yoshimi N, Sugie S, Tanaka T, Aijin W, Bunai Y, Tatematsu A, Okada T ...
Epidermal Growth Factor and Intestinal Barrier Function
Suppression of ascites formation and re-accumulation associated with human ovarian cancer by an anti-VPF monoclonal antibody in...
Optic Neuritis as Isolated Manifestation of Leptomeningeal Carcinomatosis: A Case Report and Systematic Review of Ocular...
A Case of Parovarian Serous Cystadenocarcinoma of Borderline Malignancy | Korean Journal of Obstetrics and Gynecology;: 2485...
A Case of Parovarian Serous Cystadenocarcinoma of Borderline Malignancy A Case of Parovarian Serous Cystadenocarcinoma of ... We experienced one case of parovarian serous cystadenocarcinoma of borderline malignancy, and report this with a brief review ... Full text: Available Index: WPRIM (Western Pacific) Main subject: Parovarian Cyst / Prognosis / Female / Cystadenocarcinoma, ... Full text: Available Index: WPRIM (Western Pacific) Main subject: Parovarian Cyst / Prognosis / Female / Cystadenocarcinoma, ...
JCI -
Methylation of immune synapse genes modulates tumor immunogenicity
JCI -
DNA methylation-based immune response signature improves patient diagnosis in multiple cancers
Serous cystadenocarcinoma of pancreas | JCPSP-Journal of the College of Physicians and Surgeons Pakistan. 2013; 23 (6): 430...
Serous cystic neoplasms of pancreas are relatively rare tumours. Malignancy in these tumours is even more rare which is ... and soft tissue invasion of surrounding stroma on microscopic examination and was diagnosed as serous cystadenocarcinoma of ... Serous cystadenocarcinoma of pancreas Serous cystadenocarcinoma of pancreas Muhammad Usman, Rathore; Adeel, Arif; Bilal, Umair ...
EDUCATION AND IMAGING. Hepatobiliary and Pancreatic: Long-term survival of serous cystadenocarcinoma of the pancreas with...
Hepatobiliary and Pancreatic: Long-term survival of serous cystadenocarcinoma of the pancreas with synchronous liver metastases ... Serous Cystadenocarcinoma Arising in Presumed Vitelline Duct Remnant: A Case Report and Implications in the Management of ... Hepatobiliary and Pancreatic: Long-term survival of serous cystadenocarcinoma of the pancreas with synchronous liver metastases ... Hepatobiliary and Pancreatic: Long-term survival of serous cystadenocarcinoma of the pancreas with synchronous liver metastases ...
RETRACTED ARTICLE: Metastatic ovarian papillary cystadenocarcinoma to the small intestine serous surface: report of a case of...
In the present study, a case of isolated small intestine metastasis of ovarian papillary cystadenocarcinoma was reported. A 7- ... this is the first case of small intestine serousal surface metastasis from ovarian papillary cystadenocarcinoma. ... Ovarian cystadenocarcinoma is characterized by marked heterogeneity and may be composed of an admixture of histologic growth ... features coupled with the CK7 immunoreactivity led to a diagnosis of high grade ovarian papillary cystadenocarcinoma. To the ...
LPAR1 regulates the development of intratumoral heterogeneity in ovarian serous cystadenocarcinoma by activating the PI3K/AKT...
... in human ovarian serous cystadenocarcinoma (OSC). Immunohistochemical staining was performed to detect LPAR1 expression in ... LPAR1 regulates the development of intratumoral heterogeneity in ovarian serous cystadenocarcinoma by activating the PI3K/AKT ... LPAR1 regulates the development of intratumoral heterogeneity in ovarian serous cystadenocarcinoma by activating the PI3K/AKT ... in human ovarian serous cystadenocarcinoma (OSC).. Methods. Immunohistochemical staining was performed to detect LPAR1 ...
Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma
... and mutations of EGFR and ERBB2 in serous carcinoma, the most common and aggressive type of ovarian cancer. … ... Cystadenocarcinoma, Serous / genetics* * Cystadenocarcinoma, Serous / metabolism * Cystadenocarcinoma, Serous / mortality * ... Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma J Mol Med (Berl ... Both amplification and protein overexpression of EGFR occur in serous ovarian carcinoma, but EGFR copy number has a stronger ...
Adenocarcinoma15
- Serous Microcystic Adenocarcinoma of Pancreas Infiltrating Into Spleen: A Case Report. (nih.gov)
- serous adenocarcinoma). (magichands.ru)
- Ovarian cancer is thought to arise from neoplastic changes that result in the pathologic differentiation of OSE into the established histologic subtypes, which include serous (fallopian tube-like), endometrioid (endometrium-like), and mucinous (endocervical-like) adenocarcinoma among others. (aacrjournals.org)
- Recurrent CDK7 deletions were found among ovarian serous cystadenocarcinoma, prostate adenocarcinoma, esophageal carcinoma, cholangiocarcinoma, and triple-negative breast cancer. (genomeweb.com)
- Expression of Toll-like receptor 4 in ovarian serous adenocarcinoma and correlation with clinical stage and pathological grade. (semanticscholar.org)
- ALDH1-high ovarian cancer stem-like cells can be isolated from serous and clear cell adenocarcinoma cells, and ALDH1 high expression is associated with poor prognosis. (nih.gov)
- There are four major histological subtypes in EOC, and serous adenocarcinoma and clear cell adenocarcinoma are high-grade malignancies. (nih.gov)
- We therefore analyzed ovarian CSCs/CICs from ovarian carcinoma cell lines (serous adenocarcinoma and clear cell adenocarcinoma) and primary ovarian cancer cells in this study. (nih.gov)
- Immunohistochemical staining revealed that higher ALDH1 expression levels in ovary cancer cases are related to poorer prognosis in both serous adenocarcinoma cases and clear cell adenocarcinoma cases. (nih.gov)
- Left: Patient No.4, case of stage IIIc serous adenocarcinoma. (nih.gov)
- Is distal pancreatectomy with en-bloc celiac axis resection effective for patients with locally advanced pancreatic ductal adenocarcinoma? (amedeo.com)
- Granulosa cell tumors, primary ovarian carcinoma such as mucinous and serous cystadenocarcinoma, and undifferentiated adenocarcinoma were the most prevalent malignant masses. (news-medical.net)
- Women with endometriosis are at increased risk of developing ovarian cancer, specifically ovarian endometrioid, low-grade serous, and clear-cell adenocarcinoma. (mdpi.com)
- The presence of endometriosis increases the risk of ovarian endometrioid, low-grade serous, and clear-cell adenocarcinoma by up to 8.9-fold but not high-grade serous adenocarcinoma [ 7 , 8 , 9 , 10 , 11 , 12 ]. (mdpi.com)
- Diseases associated with CLEC4C include Ovary Serous Adenocarcinoma and Blastic Plasmacytoid Dendritic Cell . (genecards.org)
Carcinoma19
- For younger women (ages 40-45 years) whose mothers were affected with endometrial malignancies, the risk of developing endometrioid carcinoma was slightly greater than the risk of developing papillary serous cystadenocarcinoma. (wiley.com)
- Uterine papillary serous carcinoma (UPSC) is an uncommon, but aggressive variant of endometrial carcinoma that has a high recurrence rate and poor response to therapy. (clinicaltrials.gov)
- It has a propensity to metastasize throughout the abdomen, similar to serous carcinoma of the ovary. (clinicaltrials.gov)
- Based on these findings and the similarities and clinical success of paclitaxel/platinum therapy in patients with ovarian serous carcinoma, this combination warrants further investigation in a prospective manner in patients with UPSC. (clinicaltrials.gov)
- The purpose of this study was to examine the frequency and clinicopathological correlations of gene amplification, protein expression, and mutations of EGFR and ERBB2 in serous carcinoma, the most common and aggressive type of ovarian cancer. (nih.gov)
- Both amplification and protein overexpression of EGFR occur in serous ovarian carcinoma, but EGFR copy number has a stronger prognostic value. (nih.gov)
- This makes EGFR amplification a potentially useful criterion for selecting patients in clinical trials testing the effect of EGFR inhibitors in serous ovarian carcinoma. (nih.gov)
- To study the prognosis of patients with stage IIIC/IV primary peritoneal serous papillary carcinoma (PSPC) (study group) compared with that of patients with epithelial ovarian carcinoma (EOC) (control group). (labome.org)
- Rare pancreatic tumors including acinar cell carcinoma, mucinous cystadenocarcinoma or serous cystadenocarcinoma. (cancer.gov)
- Analysis of Smad3 nuclear expression in microarrays of serous benign tumors, borderline tumors, and cystadenocarcinoma revealed that Smad3 expression could be used to distinguish benign and borderline tumors from carcinoma ( P = 0.006). (aacrjournals.org)
- Carriers of BRCA1 and BRCA2 mutations are at increased risk of high grade serous carcinoma and are therefore offered risk-reducing salpingo-oophorectomy (RRSO) by 40-45 years. (eur.nl)
- Most of these carcinomas are believed to arise in the fallopian tube from serous tubal intraepithelial carcinoma (STIC). (eur.nl)
- We conducted a retrospective study on the prevalence of high grade serous carcinoma and STIC in BRCA1/2 carriers presenting for RRSO, and their follow-up. (eur.nl)
- High grade serous carcinoma was more common in patients operated on after the recommended age (p = 0.03). (eur.nl)
- Two BRCA1 carriers with isolated STIC at RRSO developed peritoneal serous carcinoma N7 years later. (eur.nl)
- Identical TP53 mutations in the peritoneal serous carcinoma and the preceding STIC established their clonal origin. (eur.nl)
- High grade serous carcinoma is more common in BRCA1/2 carriers presenting for RRSO after the recommended age, and is more often of tubal origin. (eur.nl)
- Squamous cell carcinoma lung in advanced stage associated with early stage ovarian serous cystadenocarcinoma has not been described in literature. (igi-global.com)
- Although mild or moderate elevations in serum CA125 may be seen with other histological types of ovarian carcinoma, such as endometrioid or clear cell, markedly elevated levels are characteristic of serous carcinoma. (bmj.com)
Ovary1
- Most commonly, the primary site of serous cystadenocarcinoma is the ovary. (wikipedia.org)
Tumor2
- Serous cystadenocarcinoma is a type of tumor in the cystadenocarcinoma grouping. (wikipedia.org)
- Further imaging-based characterization of the possible histopathology of lesion may help in differentiating a benign pseudocyst from a cystic tumor of the pancreas, a mucinous cystic tumor from a serous tumor, and a neuroendocrine tumor from other solid neoplasias may help in determination of resectability of each of these pancreatic lesions. (springer.com)
Malignant10
- Papillary serous cystadenocarcinomas are the most common form of malignant ovarian cancer making up 26 percent of ovarian tumours in women aged over 20 in the United States. (wikipedia.org)
- Serous cystic neoplasms of the pancreas carry a realistic risk of malignancy despite the general view that they never become malignant. (biomedcentral.com)
- Also called glycogen-rich cystadenoma or microcystic adenoma is generally considered to be a benign condition although serous cystadenocarcinoma is a rare but known malignant condition described in the literature. (biomedcentral.com)
- Most of these are benign (serous cystadenomas), and in rare cases are malignant (serous cystadenocarcinoma). (biomedcentral.com)
- In 1989, George et al [ 8 ] first reported a case of serous microcystic adenoma behaving in a malignant fashion and since then, according to our best knowledge, 26 cases have been reported in the literature. (biomedcentral.com)
- Cystadenocarcinoma is a malignant form of a cystadenoma and is a malignant neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. (wikipedia.org)
- Malignant serous cystic neoplasm of the pancreas: report of a case and review of the literature. (nih.gov)
- Grade 3, Stage Iiic, Malignant Papillary Serous Adenocarcino. (atcc.org)
- Amongst benign tumors, serous cystadenoma was the most frequent subtype, while for the malignant tumors serous cystadenocarcinoma was the commonest. (thefreelibrary.com)
- Cystadenocarcinoma ( papillary cystadenocarcinoma ) of the salivary gland is a rare malignant neoplasm. (labome.org)
Pancreas6
- Rare occurrence in the pancreas has been reported, although this is not typical, with the majority of microcystic pancreatic masses representing alternate disease processes such as the more benign serous cystadenoma. (wikipedia.org)
- A 86-year old patient known to have a serous cystadenoma of the pancreas treated conservatively through a close clinical and radiological follow up which was unattended for 4 years ending up to our emergency department suffering an acute abdomen. (biomedcentral.com)
- Risk of malignancy in serous cystic neoplasms of the pancreas. (nih.gov)
- Serous cystadenocarcinoma of the pancreas with portal thrombosis. (nih.gov)
- Serous cystic neoplasms of pancreas are relatively rare tumours. (bvsalud.org)
- Hepatobiliary and Pancreatic: Long-term survival of serous cystadenocarcinoma of the pancreas with synchronous liver metastases after aggressive surgical resection. (semanticscholar.org)
Tumors2
- According to the latest WHO classification these tumors are called serous cystic neoplasms, which are cystic epithelial neoplasms composed of glycogen-rich, epithelial cells that produce a watery fluid similar to serum. (biomedcentral.com)
- Hepatic metastasis of serous cystadenocarcinoma resected 4 years after operation of primary tumors. (nii.ac.jp)
Cystic3
- The first type is considered the serous cystic neoplasm and the serous cystadenoma represents numerically the most common entity. (biomedcentral.com)
- Serous adenoma has four variants: macrocystic serous cystic neoplasm, solid serous neoplasm, von Hippel-Lindau (VHL)-associated serous cystic neoplasm, and mixed serous-neuroendocrine neoplasm. (biomedcentral.com)
- About 25% of adnexal growths are endometriomas, 33% are mature cystic teratomas, and the rest are functional cysts or serous or mucinous cystadenomas. (news-medical.net)
Patients with ovarian serous1
- The methylation array data of 551 patients with ovarian serous cystadenocarcinoma (OSC) in The Cancer Genome Atlas (TCGA) database were assessed in this study to explore the methylation biomarkers associated with prognosis and improve the prognosis of patients. (cdc.gov)
Malignancy1
- We experienced one case of parovarian serous cystadenocarcinoma of borderline malignancy , and report this with a brief review of the literatures . (bvsalud.org)
Pathology1
- Ovarian papillary serous cystadenocarcinoma at WebPath, The Internet Pathology Laboratory for Medical Education at Mercer University School of Medicine. (wikipedia.org)
Metastasis3
- Gastric metastasis from ovarian serous cystadenocarcinoma is extremely rare. (dovepress.com)
- In the present study, a case of isolated small intestine metastasis of ovarian papillary cystadenocarcinoma was reported. (biomedcentral.com)
- To the best of our knowledge, this is the first case of small intestine serousal surface metastasis from ovarian papillary cystadenocarcinoma. (biomedcentral.com)
Pancreatic serous3
- The patient was in a close clinical and radiological follow up for monitoring a pancreatic serous cystadenoma diagnosed incidentally with a computed tomography (CT) scan 10 years earlier. (biomedcentral.com)
- Pancreatic serous cystadenocarcinoma with invasive growth into the colon and spleen. (nih.gov)
- Imaging of pancreatic serous cystadenocarcinoma. (nih.gov)
Psammoma bodies1
- Papillary serous cystadenocarcinomas may exhibit psammoma bodies upon histopathology. (wikipedia.org)
Diagnosis1
- The histopathologic features coupled with the CK7 immunoreactivity led to a diagnosis of high grade ovarian papillary cystadenocarcinoma. (biomedcentral.com)
Acinar1
- Ovarian cystadenocarcinoma is characterized by marked heterogeneity and may be composed of an admixture of histologic growth patterns, including acinar, papillary and solid. (biomedcentral.com)
Histopathology1
- She underwent a liver resection, and histopathology confirmed a serous biliary cystadenoma. (uwi.edu)
Metastases1
- We report a case of serous cystadenocarcinoma with extensive local invasion and liver metastases. (biomedcentral.com)
Adenocarcinomas2
- We isolated ovarian CSCs/CICs as an aldehyde dehydrogenase 1 high (ALDH1(high)) population from 6 EOC cell lines (3 serous adenocarcinomas and 3 clear cell adenocarcinomas) by the ALDEFLUOR assay. (nih.gov)
- Thus, ovarian endometrioid, low-grade serous, and clear-cell adenocarcinomas are considered endometriosis-associated ovarian cancers. (mdpi.com)
Immunohistochemical1
- Immunohistochemical and ultrastructural findings in a rare case of papillary cystadenocarcinoma arising from the left sublingual gland of a 55-year-old Japanese man are reported. (labome.org)
Heterogeneity1
- To explore the role of lysophosphatidic acid receptor 1 (LPAR1) and its correlation with the PI3K/AKT pathway in the development of intratumoral heterogeneity (ITH) in human ovarian serous cystadenocarcinoma (OSC). (biomedcentral.com)
Ovarian3
- Images which correlate to the Ovarian serous cystadenocarcinoma tissue data in the TCGA Data Portal are continuing to be gathered for submission to TCIA . (cancerimagingarchive.net)
- However, the role of YAP1 as an oncogene has not yet been fully investigated in a large group of ovarian serous cystadenocarcinoma (OSC) patients, who account for the largest proportion of malignant ovarian cancer cases (17,18). (a-443654.com)
- The mass spectrometry (MS) data in this dataset was imported to CAVATICA in 2017 and consists of four [TCGA cancer types](https://gdc.cancer.gov/resources-tcga-users/tcga-code-tables/tcga-study-abbreviations) (Ovarian serous cystadenocarcinoma, Breast invasive carcinoma, Colon adenocarcinoma, Rectum adenocarcinoma) that are included in the CPTAC public project. (cavatica.org)